These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23678271)

  • 1. Current smoking is associated with a poor visual acuity improvement after intravitreal ranibizumab therapy in patients with exudative age-related macular degeneration.
    Lee S; Song SJ; Yu HG
    J Korean Med Sci; 2013 May; 28(5):769-74. PubMed ID: 23678271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes.
    Małgorzata F; Stankiewicz A
    Med Sci Monit; 2011 Sep; 17(9):CR485-90. PubMed ID: 21873944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.
    Matsumiya W; Honda S; Kusuhara S; Tsukahara Y; Negi A
    BMC Ophthalmol; 2013 Apr; 13():10. PubMed ID: 23557322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early visual impacts of optical coherence tomographic parameters in patients with age-related macular degeneration following the first versus repeated ranibizumab injection.
    Sayed KM; Naito T; Nagasawa T; Katome T; Mitamura Y
    Graefes Arch Clin Exp Ophthalmol; 2011 Oct; 249(10):1449-58. PubMed ID: 21494878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration.
    Shiragami C; Ono A; Kobayashi M; Manabe S; Yamashita A; Shiraga F
    Medicine (Baltimore); 2014 Oct; 93(18):e116. PubMed ID: 25319441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis.
    Canan H; Sızmaz S; Altan-Yaycıoğlu R; Sarıtürk C; Yılmaz G
    Clin Interv Aging; 2014; 9():141-5. PubMed ID: 24453484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD.
    Koch KR; Muether PS; Hermann MM; Hoerster R; Kirchhof B; Fauser S
    Graefes Arch Clin Exp Ophthalmol; 2012 Feb; 250(2):201-9. PubMed ID: 21901296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme.
    Heimes B; Lommatzsch A; Zeimer M; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
    Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):639-44. PubMed ID: 20890777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.
    Monés J; Biarnés M; Trindade F; Casaroli-Marano R
    Graefes Arch Clin Exp Ophthalmol; 2012 Dec; 250(12):1737-44. PubMed ID: 22527314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population.
    Chang W; Noh DH; Sagong M; Kim IT
    Mol Vis; 2013; 19():702-9. PubMed ID: 23559864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
    Chan CK; Jain A; Sadda S; Varshney N
    Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration.
    Panos GD; Gatzioufas Z; Petropoulos IK; Dardabounis D; Thumann G; Hafezi F
    Drug Des Devel Ther; 2013; 7():565-9. PubMed ID: 23874084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load.
    Geirsdottir A; Jonsson O; Thorisdottir S; Helgadottir G; Jonasson F; Stefansson E; Sigurdsson H
    Br J Ophthalmol; 2012 Mar; 96(3):444-7. PubMed ID: 21856691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS; Daftari I; Phillips T; Morse LS
    Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.
    Hufendiek K; Hufendiek K; Panagakis G; Helbig H; Gamulescu MA
    Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.